LinkedIn Profile

Access Proteon Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:prto 1070053 Oct 30th, 2020 12:00AM Proteon Therapeutics 1.1K 10.00 Open Biotechnology Oct 30th, 2020 12:40PM Oct 30th, 2020 12:40PM Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD). Open Open 200 West St Waltham MA US 02451 Proteon Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:prto 1070053 Oct 29th, 2020 12:00AM Proteon Therapeutics 1.1K 10.00 Open Biotechnology Oct 29th, 2020 12:53PM Oct 29th, 2020 12:53PM Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD). Open Open 200 West St Waltham MA US 02451 Proteon Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:prto 1070053 Oct 28th, 2020 12:00AM Proteon Therapeutics 1.1K 10.00 Open Biotechnology Oct 28th, 2020 04:36PM Oct 28th, 2020 04:36PM Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD). Open Open 200 West St Waltham MA US 02451 Proteon Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:prto 1070053 Oct 27th, 2020 12:00AM Proteon Therapeutics 1.1K 11.00 Open Biotechnology Oct 27th, 2020 10:35AM Oct 27th, 2020 10:35AM Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD). Open Open 200 West St Waltham MA US 02451 Proteon Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:prto 1070053 Oct 26th, 2020 12:00AM Proteon Therapeutics 1.1K 11.00 Open Biotechnology Oct 26th, 2020 03:36PM Oct 26th, 2020 03:36PM Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD). Open Open 200 West St Waltham MA US 02451 Proteon Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:prto 1070053 Oct 25th, 2020 12:00AM Proteon Therapeutics 1.1K 11.00 Open Biotechnology Oct 25th, 2020 12:30PM Oct 25th, 2020 12:30PM Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD). Open Open 200 West St Waltham MA US 02451 Proteon Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:prto 1070053 Oct 24th, 2020 12:00AM Proteon Therapeutics 1.1K 11.00 Open Biotechnology Oct 24th, 2020 02:40PM Oct 24th, 2020 02:40PM Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD). Open Open 200 West St Waltham MA US 02451 Proteon Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:prto 1070053 Oct 23rd, 2020 12:00AM Proteon Therapeutics 1.1K 11.00 Open Biotechnology Oct 23rd, 2020 11:59AM Oct 23rd, 2020 11:59AM Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD). Open Open 200 West St Waltham MA US 02451 Proteon Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:prto 1070053 Oct 22nd, 2020 12:00AM Proteon Therapeutics 1.1K 11.00 Open Biotechnology Oct 22nd, 2020 09:19AM Oct 22nd, 2020 09:19AM Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD). Open Open 200 West St Waltham MA US 02451 Proteon Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:prto 1070053 Oct 21st, 2020 12:00AM Proteon Therapeutics 1.1K 11.00 Open Biotechnology Oct 20th, 2020 10:53PM Oct 20th, 2020 10:53PM Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in PATENCY-1 and PATENCY-2, two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis. Proteon has also completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD). Open Open 200 West St Waltham MA US 02451 Proteon Therapeutics Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.